T Cell Lymphoma clinical trials at UC Irvine

• A Study of Duvelisib in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)

  Sorry, in progress, not accepting new patients

  This is a multi-center, parallel cohort, open-label, Phase 2 study of duvelisib, an oral dual inhibitor of PI3K-δ,γ, in patients with relapsed or refractory Peripheral T cell Lymphoma (PTCL).

  Irvine, California and other locations

• Mogamulizumab Q4week Dosing in Participants With R/R CTCL

  Sorry, not currently recruiting here

  This is an open-label, multicenter, Phase 2 study to evaluate the safety and tolerability of mogamulizumab given Q4W following initial weekly induction in adult participants with relapsed/refractory MF and SS subtypes of CTCL. The study is composed of a 28-day Screening Period during which participants are screened for entry into this study, followed by a treatment period of up to 2 years from Cycle 1 Day 1.

  Irvine, California and other locations

Last updated: July 21, 2021